Dublin, Ireland, 20th March 2015: Dignity Sciences (DS) is today presenting a late-breaking news abstract at the annual meeting of the American Association of Dermatology (AAD) in San Francisco (March 20th-24th, 2015).
The abstract, entitled “The effective and safe use of DS107 cream in patients with atopic dermatitis: first results from a Phase IIa clinical trial”, will be presented in Room 2202 in the West Building of the Moscone Center from 4.50pm to 5.30pm PDT.
The abstract highlights the key primary and secondary efficacy end points from the company’s Phase IIa DS107 topical trial in atopic dermatitis completed last year. Noteworthy conclusions from the study included:
• The changes were statistically significant from baseline in all treatment groups. Although the trial was not powered to show statistical significance, an overall dose related improvement in the change from baseline to end of treatment (28 days) for the primary efficacy variable, Modified Eczema Area and Severity Index (mEASI), was observed.
• Improvements in the primary and secondary efficacy variables showed no evidence of plateau over the 28 day trial period.
• Topical DS107 showed significant reductions in itch (VAS scores), which make it particularly effective in the management of pruritus, which has the greatest impact on a patient’s quality of life.
Encouraged by the data, DS is initiating a proof of concept, topical Phase IIa trial with DS107 in Germany later this year. This prevention and steroid sparing study will start recruiting in May 2015 and is expected to report results by the end of the year.
In addition, DS is carrying out a DS107 oral Phase II trial for atopic dermatitis in the United States and Canada. Patient recruitment has started for the study and headline results are expected by the end of 2015.
About Dignity Sciences
Dignity Sciences, headquartered in Dublin, Ireland, is a privately held drug discovery and development company working on new medicines that improve the quality of life for people with diseases for which existing therapies are ineffective or unsafe. DS has developed a proprietary bioactive lipid technology platform. In addition to the Company’s first generation compound DS107, the Company is developing an anti-fibrotic compound; DS102 for NASH (Non Alcoholic Steatohepatitis), fatty liver disease and potentially other respiratory disorders.
Contacts:
Dignity: Mark O’Neill, Commercial Director, 0035312933590
FTI Consulting: Julia Phillips/Rob Winder/Natalie Garland-Collins, 00442037271000
Help employers find you! Check out all the jobs and post your resume.
